

Date: 31 October 2022

Quarterly Report - Update

ASX Announcement

ABN 11 124 426 339

Level 3, 2-4 Ross Place, South Melbourne, VIC 3205

P: +61 (3) 9673 9690 E: <u>corporate@purifloh.com</u>

www.purifloh.com

Operation Report for Quarter Ended 30 September 2022

During the quarter the Company has continued its product Research and Development based out of Victoria as follows:

R&D and Independent testing

R&D efforts have sought an FRG based air purifier without neutralizer filters which would significantly reduce the size and cost of the equipment for sale. The initial tests have proven fruitful with positive results from independently conducted tests announced during the quarter. The key result is the 150% improvement in rate of removal of airborne microbes when compared with standard HEPA based filtration. Ambient ozone concentration was also measured and shown to be well below levels prescribed by Australian national air quality standards.

Testwork is ongoing on the ACERT (Air Conditioning Environmental Remediation) equipment working towards validation of ACERT's ability to destroy surface microbes.

The Company also notes recent commentary as to the World Health Organisation compiling a list of fungi that pose a growing risk to human health, with the fungi aspergillus fumigatus specifically named.¹

PurifIOH notes the ability of its FRG to destroy *Aspergillus fumigatus* as specifically referred in Report on Tuberculosis Trials released to the ASX on 27 May 2019 as well as its ability to remove ambient *Aspergillus niger* spores referred in Aerosol Test Results released to the ASX on 17 April 2018. The Company plans to update these trials during the current quarter and also examine the FRG's ability in destroying these microbes and their spores on surfaces in addition to ambient air.

PurifIOH continues to refine and research both surface and air treatment techniques that make use of the FRG.

¹ 'WHO Releases first-ever list of Health-Threatening Fungi' October 25 2022 https://www.who.int/news/item/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi



Partnerships and commercialization:

The company has continued its activities with Osmoflo as a potential water treatment partner during the quarter. Based on the data collected in the past 8 months, Osmoflo is set to provide feedback in the near future, potentially leading to talks about next steps and the future of our partnership.

The company continues to seek other strategic partnerships for installation and maintenance of the ACERT and Air Purifier products together with partnership options on manufacturing and distribution. The company is also continuing design activities on the two products and seeks OEM partnerships for the addition of the filterless FRG to existing HEPA based devices.

Comment on Appendix 4C - Quarterly Cashflow Report

- The Company notes that it has continued to operate on funds drawn down from its Dilato facility.
- The Company drew down an additional \$54,000 only during the quarter and retains a facility through Dilato of \$2.363M.
- Funds spent during the quarter were mainly on corporate costs and fees for parties working on R&D activities within the Company.
- Director fees continue to be accrued.

This ASX announcement was authorized and approved by the Chairman of PurifIOH Limited.

End

For further information:

Carl Le Souef (Director) Melbourne, Australia + 613 9673 9673

